Vol 6, No 4 (2002)
Original paper
Published online: 2002-10-18

open access

Page views 1089
Article views/downloads 1812
Get Citation

Connect on Social Media

Connect on Social Media

Antihypertensive Efficacy and Safety of Lacidipine in the Treatment of Patients with Mild to Moderate Essential Hypertension - Multi-Center Study POL-LACY

Andrzej Januszewicz, Jarosław Buczek, Magdalena Makowiecka-Cieśla, Aleksander Prejbisz, Agnieszka Gbur w imieniu Grupy Badaczy
Nadciśnienie tętnicze 2002;6(4):291-298.

Abstract

Background Lacidipine is an orally administered calcium channel blocker of the dihydropyridine class, which shows selectivity for vascular smooth muscle and has a long duration of action. The aim of multi-center study POL-LACY was to establish antihypertensive effect and safety of lacidipine given once a day 2 to 6 mg in patient with mild to moderate hypertension.
Material and methods The study was an open, multi-centre study in 37 Polish medical centers. 470 patients with mild to moderate hypertension were included into the study. 7 days qualification period was followed by 8 weeks of active treatment. During qualification period antihypertensive treatment was withdrawn and patients underwent clinical evaluation. In the phase of active treatment patients were treated with lacidipine (Lacipil®, GlaxoSmithKline Pharmaceuticals) starting from dose of 4 mg or 2 mg in patients older than 65 years. The dose could be tritated up to 6 or 4 mg if there was no normalization of BP level after 4 weeks of treatment. Normalization of BP was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg. During phase of active treatment, after 4 and 8 weeks, efficacy and safety of treatment was evaluated.
Results 446 patients completed the study (255 M, 191 F; mean age 52 ± 13 years). The mean baseline BP value was 157/98 mm Hg. At the end of the study 9,9% of patients were treated with 2 mg, 72,9% of patients with 4 mg and 17,3% of patients with 6 mg of lacidipine. After 8 weeks lacidipine decreased significantly systolic BP by 23 mm Hg (p < 0,0001) and diastolic BP by 15 mm Hg (p < 0,0001) in the sitting position. Antihypertensive effect of lacidipine was not influenced by sex, age and BMI. Full normalization of BP was achieved in 71% of patients. Pulse pressure was significantly reduced by 8 mm Hg (p < 0,0001). Lacidipine was well tolerated, 21% of patients experienced adverse events.
Conclusions Lacidipine is a highly effective drug in the monotherapy of mild to moderate essential hypertension. Antihypertensive effect of lacidipine is not influenced by age, sex and BMI. Lacidipine has a positive effect on pulse pressure. Lacidipine is well tolerated by patients. In conclusion, presented data point at the lacidipine as a useful drug in monotherapy of essential hypertension.

Article available in PDF format

View PDF (Polish) Download PDF file